CEMET

UNIVADIS - CEMET /univadis/CEMET.md

ATC

Μορφές:
Μορφές: INJ.SO.INF

Δραστικές

Δελτίο Τιμών 05/2018

Ημερομηνία barcode code περιεχομενο τιμή παραγωγός χονδρική λιανική
05/2018 2803006001044 300600104 CEMET SO.INJ.INF 2MG/1ML BTx5 AMPS x5ML 4.80 05.04 6.94
05/2018 2803006001068 300600106 CEMET SO.INJ.INF 2MG/1ML BTx5AMPS x10ML 8.85 9.28 12.78
05/2018 2803006002010 300600201 CEMET SO.INJ.INF 5MG/1ML BTx1 VIAL x30ML 5.40 5.66 7.80
  • DRUGBANK - Cisatracurium Besylate
  • indication:

    For inpatients and outpatients as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the ICU.

  • pharmacology:

  • mechanism:

    Cisatracurium Besylate binds to the nicotinic acetycholine (cholinergic) receptors in the motor endplate and blocks access to the receptors. In the process of binding, the receptor is actually activated - causing a process known as depolarization. Since it is not degraded in the neuromuscular junction, the depolarized membrane remains depolarized and unresponsive to any other impulse, causing muscle paralysis.

  • toxicity:

    Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.

  • absorprion:

  • halflife:

    Elimination half-life of 22 minutes.

  • roouteelimination:

    Biliary and urinary excretion were the major routes of excretion of radioactivity (totaling >90% of the labeled dose within 7 hours of dosing), of which atracurium represented only a minor fraction.

  • volumedistribution:

  • clearance: